|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
81,510,000 |
Market
Cap: |
2.05(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$17.69 - $45.07 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Beam Therapeutics is a biotechnology company. Co. has identified four development candidates to date: three from its ex vivo platform, with two candidates targeting hemoglobinopathies and one candidate targeting T-cell leukemia, and one from its in vivo platform targeting glycogen storage disease. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
61,250 |
176,420 |
1,153,728 |
1,608,235 |
Total Sell Value |
$1,499,251 |
$5,276,873 |
$34,770,451 |
$52,163,962 |
Total People Sold |
2 |
5 |
6 |
6 |
Total Sell Transactions |
3 |
10 |
17 |
39 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Fmr Corp |
See Remark 1 |
|
2021-08-06 |
4 |
A |
$0.00 |
$0 |
I/I |
455,414 |
1,160,583 |
|
- |
|
Fmr Corp |
See Remark 1 |
|
2021-08-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(752,847) |
0 |
|
- |
|
Evans John M. |
CEO |
|
2021-07-07 |
4 |
AS |
$100.69 |
$2,696,826 |
D/D |
(25,000) |
1,021,525 |
|
- |
|
Evans John M. |
CEO |
|
2021-07-07 |
4 |
OE |
$1.03 |
$25,750 |
D/D |
25,000 |
1,046,525 |
|
- |
|
Cooper Graham K |
Director |
|
2021-07-06 |
4 |
AS |
$115.38 |
$315,263 |
D/D |
(2,614) |
0 |
|
- |
|
Cooper Graham K |
Director |
|
2021-07-06 |
4 |
OE |
$17.00 |
$44,438 |
D/D |
2,614 |
2,614 |
|
- |
|
Nelsen Robert |
10% Owner |
|
2021-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
8,052 |
28,111 |
|
- |
|
Nelsen Robert |
10% Owner |
|
2021-06-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(400,000) |
2,921,519 |
|
- |
|
Burow Kristina |
Director |
|
2021-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,011 |
12,067 |
|
- |
|
Burow Kristina |
Director |
|
2021-06-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(400,000) |
2,921,519 |
|
- |
|
Evans John M. |
Chief Executive Officer |
|
2021-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
32 |
1,021,525 |
|
- |
|
Burow Kristina |
Director |
|
2021-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,011 |
10,056 |
|
- |
|
Burow Kristina |
Director |
|
2021-06-29 |
4 |
D |
$0.00 |
$0 |
I/I |
(400,000) |
3,121,519 |
|
- |
|
Nelsen Robert |
10% Owner |
|
2021-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
8,052 |
23,425 |
|
- |
|
Nelsen Robert |
10% Owner |
|
2021-06-29 |
4 |
D |
$0.00 |
$0 |
I/I |
(400,000) |
3,121,519 |
|
- |
|
Burrell Terry-Ann |
CFO |
|
2021-06-28 |
4 |
AS |
$103.86 |
$4,846,016 |
D/D |
(45,000) |
24,809 |
|
- |
|
Burrell Terry-Ann |
CFO |
|
2021-06-28 |
4 |
OE |
$13.68 |
$615,600 |
D/D |
45,000 |
69,809 |
|
- |
|
Ciaramella Giuseppe |
President & CSO |
|
2021-06-28 |
4 |
AS |
$103.83 |
$8,435,365 |
D/D |
(78,580) |
44,761 |
|
- |
|
Ciaramella Giuseppe |
President & CSO |
|
2021-06-28 |
4 |
OE |
$17.00 |
$1,335,860 |
D/D |
78,580 |
123,341 |
|
- |
|
Evans John M. |
Chief Executive Officer |
|
2021-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
32 |
1,021,493 |
|
- |
|
Cooper Graham K |
Director |
|
2021-06-28 |
4 |
AS |
$105.37 |
$1,280,897 |
D/D |
(12,045) |
0 |
|
- |
|
Cooper Graham K |
Director |
|
2021-06-28 |
4 |
OE |
$17.00 |
$204,765 |
D/D |
12,045 |
12,045 |
|
- |
|
Evans John M. |
Chief Executive Officer |
|
2021-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
32 |
1,021,461 |
|
- |
|
Burow Kristina |
Director |
|
2021-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,011 |
8,045 |
|
- |
|
Burow Kristina |
Director |
|
2021-06-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(400,000) |
3,321,519 |
|
- |
|
169 Records found
|
|
Page 5 of 7 |
|
|